ImmunoGen touts a PhIII comeback in ovarian cancer, eyeing a 2022 accelerated approval

When ImmunoGen’s lead antibody-drug conjugate flunked a Phase III study in ovarian cancer a couple years ago, the company clung to hope that it would perform better in a subgroup of patients with high folate receptor alpha (FRα) expression.

On Tuesday, researchers uncorked topline Phase III results suggesting it was...

Click to view original post